A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)

Trial Profile

A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs SYNT 001 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions
  • Acronyms WAIHA
  • Sponsors Syntimmune
  • Most Recent Events

    • 01 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Jan 2019.
    • 01 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 01 Nov 2017 According to a Syntimmune media release, topline data from this trial is expected in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top